Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Bortezomib in Taiwanese Patients with Multiple Myeloma
NCT02268890Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of bortezomib in multiple myeloma (MM), sponsored by Johnson & Johnson. Started Dec 2014; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02268890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268890.